Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival

Rita A. Mukhtar(University of California, San Francisco), Hope S. Rugo(City of Hope), Kelly Fahrner-Scott(Mayo Clinic in Arizona), Matina Elise Mamounas(University of California, San Francisco), Cheryl A. Ewing(University of California, San Francisco), Yunn‐Yi Chen(University of Vermont), Laura J. Esserman(University of California, San Francisco), Jasmine Wong, Gregor Krings(Cleveland Clinic), Michael Alvarado(University of California, San Francisco)
Breast Cancer Research and Treatment
April 2, 2020
10.1007/s10549-020-05606-5
Cited by 7

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k